Abstract | BACKGROUND: OBJECTIVE: METHODS: Literature published in peer-reviewed journals during the past 2 decades that identified and characterized DDE enzymes, including RAG proteins, RISC and RNA silencing, RNAse H, retroviral integrases, transposases, and a putative DDE recombinase required for herpes virus replication, was selectively reviewed and summarized by the author. RESULTS: CONCLUSION: Because of their critical role in acquired and innate immunity, the DDE recombinases are attractive targets for novel pharmacologic therapies. Currently, retroviral integrase inhibitors in clinical trial for human immunodeficiency virus infection appear to be safe and effective and could provide a paradigm for inactivating DDE sites in other viral pathogens, as well as RAG and RISC.
|
Authors | David H Dreyfus |
Journal | Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
(Ann Allergy Asthma Immunol)
Vol. 97
Issue 5
Pg. 567-76; quiz 576-8, 602
(Nov 2006)
ISSN: 1081-1206 [Print] United States |
PMID | 17165262
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Homeodomain Proteins
- RNA-Induced Silencing Complex
- Recombinases
- RAG-1 protein
- Integrases
- VDJ Recombinases
|
Topics |
- Animals
- Homeodomain Proteins
(metabolism, physiology)
- Humans
- Immunity
(physiology)
- Immunity, Innate
(physiology)
- Integrases
(metabolism, physiology)
- Models, Molecular
- RNA-Induced Silencing Complex
(metabolism, physiology)
- Recombinases
(metabolism, physiology)
- VDJ Recombinases
(metabolism, physiology)
|